Literature DB >> 23515098

In focus: MLL-rearranged leukemia.

J de Boer1, V Walf-Vorderwülbecke, O Williams.   

Abstract

The molecular mechanisms underlying oncogenesis in leukemias associated with rearrangement of the Mixed Lineage Leukemia (MLL) gene have received a considerable amount of attention over the last two decades. In this review we will focus on recent studies, published over the past year, that reveal new insights into the multi-protein complexes formed by MLL and MLL fusion proteins, the role of epigenetic deregulation in MLL fusion function, downstream transcriptional target genes, the importance of the leukemia cell of origin, the role played by microRNAs, cooperating mutations and the implications that recent research has for the therapy of MLL-rearranged leukemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23515098     DOI: 10.1038/leu.2013.78

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  35 in total

1.  NF-κB-dependent DNA damage-signaling differentially regulates DNA double-strand break repair mechanisms in immature and mature human hematopoietic cells.

Authors:  D Kraft; M Rall; M Volcic; E Metzler; A Groo; A Stahl; L Bauer; E Nasonova; D Salles; G Taucher-Scholz; H Bönig; C Fournier; L Wiesmüller
Journal:  Leukemia       Date:  2015-02-05       Impact factor: 11.528

Review 2.  Getting down to the core of histone modifications.

Authors:  Antonia P M Jack; Sandra B Hake
Journal:  Chromosoma       Date:  2014-05-02       Impact factor: 4.316

3.  PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.

Authors:  J Zhou; J Wu; B Li; D Liu; J Yu; X Yan; S Zheng; J Wang; L Zhang; L Zhang; F He; Q Li; A Chen; Y Zhang; X Zhao; Y Guan; X Zhao; J Yan; J Ni; M A Nobrega; B Löwenberg; R Delwel; P J M Valk; A Kumar; L Xie; D G Tenen; G Huang; Q-F Wang
Journal:  Leukemia       Date:  2013-12-26       Impact factor: 11.528

4.  Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia.

Authors:  M-P Garcia-Cuellar; E Füller; E Mäthner; C Breitinger; K Hetzner; L Zeitlmann; A Borkhardt; R K Slany
Journal:  Leukemia       Date:  2014-01-21       Impact factor: 11.528

Review 5.  Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.

Authors:  Alejandra Sanjuan-Pla; Clara Bueno; Cristina Prieto; Pamela Acha; Ronald W Stam; Rolf Marschalek; Pablo Menéndez
Journal:  Blood       Date:  2015-10-13       Impact factor: 22.113

Review 6.  Origins of aberrant DNA methylation in acute myeloid leukemia.

Authors:  T Schoofs; W E Berdel; C Müller-Tidow
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

Review 7.  Targeting novel signaling pathways for resistant acute myeloid leukemia.

Authors:  Kathleen M Sakamoto; Steven Grant; Diana Saleiro; John D Crispino; Nobuko Hijiya; Francis Giles; Leonidas Platanias; Elizabeth A Eklund
Journal:  Mol Genet Metab       Date:  2014-12-05       Impact factor: 4.797

Review 8.  Targeting the histone orthography of cancer: drugs for writers, erasers and readers.

Authors:  Laia Simó-Riudalbas; Manel Esteller
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

9.  NAD as a genotype-specific drug target.

Authors:  Szu-Chieh Mei; Charles Brenner
Journal:  Chem Biol       Date:  2013-11-21

Review 10.  Playing TETris with DNA modifications.

Authors:  Benjamin Delatte; Rachel Deplus; François Fuks
Journal:  EMBO J       Date:  2014-05-13       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.